Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11913013 Chimpanzee adenoviral vector-based filovirus vaccines

Patent 11913013 was granted and assigned to Sabin Vaccine Institute on February, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

Sabin Vaccine Institute

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Alfredo Nicosia0

Stefano Colloca0

Riccardo Cortese0

Gary J. Nabel0

Cheng Cheng0

Clement Asiedu0

Nancy J. Sullivan0

Virginia Ammendola0

Date of Patent

February 27, 2024

0

Patent Application Number

173894210

Date Filed

July 30, 2021

0

Patent Citations

US Patent 8101739 Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector

0

US Patent 9718863 Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof

0

US Patent 8216834 Chimpanzee adenovirus vaccine carriers

0

Patent Primary Examiner

Jeffrey S. Parkin

0

CPC Code

C12N 2760/14134

0

C12N 2710/10341

0

0

0

0

Patent abstract

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11913013 Chimpanzee adenoviral vector-based filovirus vaccines

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool